1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
Interventional Oncology Market by Product, Procedures, Cancer - Global Forecast to 2024

Interventional Oncology Market by Product, Procedures, Cancer - Global Forecast to 2024

  • March 2019
  • 181 pages
  • ID: 5758939
  • Format: PDF

Summary

Table of Contents

Search Inside

The global interventional oncology market is projected to grow at a CAGR of 6.8% during the forecast period
Interventional oncology refers to the use of minimally invasive procedures performed for the diagnosis, treatment, or palliative care of cancer. The global interventional oncology market is projected to reach USD 2.9 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 6.8% from 2019 to 2024. The growth of this market is primarily driven by the rising preference for minimally invasive procedures, expansion of the target patient population, increasing public-private funding and government support for cancer research, technological advancements in the field of interventional oncology, and increasing government investments and funding for interventional oncology and related cancer research. However, the dearth of well-trained and skilled radiologists and oncologists, high costs of interventional oncology procedures, and unfavorable regulations are expected to limit market growth to a certain extent.

The transcatheter arterial radioembolization TARE or selective internal radiation therapy SIRT segment accounted for the largest share of the global interventional oncology market during the forecast period
On the basis of procedure, the interventional oncology market is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization TACE, transcatheter arterial radioembolization TARE or selective internal radiation therapy SIRT, and transcatheter arterial embolization TAE or bland embolization procedures. In 2018, the TARE/SIRT procedures segment accounted for the largest share of this market majorly due to the rising prevalence of cancer, increasing demand for minimally invasive procedures, growing adoption of embolization procedures, and the clinical efficacy of Yttrium-90 radioembolic agents which are used in these procedures.

The liver cancer segment accounted for the largest share of the interventional oncology market during the forecast period
Based on cancer type, the interventional oncology market is segmented into liver cancer, lung cancer, kidney cancer, bone cancer, and other cancers.The other cancers segment includes pediatric cancer, prostate cancer, and breast cancer.

The liver cancer segment accounted for the largest share in the interventional oncology market in 2018.

Europe accounted for the second-largest share of the global market in 2018
The interventional oncology market is segmented into five major regions, namely North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.Europe accounted for the second-largest share in 2018.

The rising incidence of cancer, coupled with the growing geriatric population in Europe, is a key factor propelling the demand for interventional oncology products in this region.Prominent market players are focusing on improving the quality of patient care across Europe by commercializing advanced products, investing in technological innovations, and partnering with other institutions and organizations for spreading cancer awareness.

This is another major factor driving market growth.

Breakdown of supply-side primary interviews:
• By Company Type: Tier 1 - 25%, Tier 2 - 30%, and Tier 3 - 45%
• By Designation: C-level - 26%, Director-level - 30%, and Others - 44%
• By Region: North America - 34%, Europe - 26%, APAC - 23%, and RoW - 17%

The major players in the market include Medtronic Ireland, Boston Scientific US, BTG plc UK, Merit Medical Systems US, and Terumo Japan. The other prominent players operating in the overall interventional oncology market include AngioDynamics US, Ethicon a part of J&J US, Teleflex US, Cook Medical US, HealthTronics US, MedWaves Medical US, Sanarus US, IMBiotechnologies Canada, Trod Medical US, IceCure Medical Israel, Mermaid Medicals Denmark, and Interface Biomaterials BV Netherlands, among others.

Research Coverage
This report studies the interventional oncology market based on products, procedure, cancer type, and region.The report also studies factors such as drivers, restraints, opportunities, and challenges affecting market growth.

It also provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to four main regions and the respective countries in these regions.

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market shares of top players, and company profiles, which together form basic views.It also analyzes the competitive landscape; emerging segments of the interventional oncology market; and high-growth regions and their drivers, restraints, challenges, and opportunities.

The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Choriocarcinoma (Gestational Trophoblastic Neoplasia) Global Clinical Trials Review, H2, 2018

Choriocarcinoma (Gestational Trophoblastic Neoplasia) Global Clinical Trials Review, H2, 2018

  • $ 2500
  • December 2018

Choriocarcinoma (Gestational Trophoblastic Neoplasia) Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Choriocarcinoma (Gestational Trophoblastic Neoplasia) Global ...

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy ...

Brain Cancer Global Clinical Trials Review, H2, 2018

Brain Cancer Global Clinical Trials Review, H2, 2018

  • $ 2500
  • December 2018

Brain Cancer Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Brain Cancer Global Clinical Trials Review, H2, 2018" provides an overview of Brain Cancer clinical trials ...


ref:plp2019

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on